StockCall Study on Merck & Co., Pfizer, Johnson & Johnson, and AbbVie PR Newswire LONDON, March 12, 2013 LONDON, March 12, 2013 /PRNewswire/ -- On Monday, drug stocks ended mostly higher as the Dow Jones posted yet another record high finish. Major pharmaceutical companies such as Merck & Co. Inc. (NYSE: MRK), Pfizer Inc. (NYSE: PFE), Johnson & Johnson (NYSE: JNJ), and AbbVie Inc. (NYSE: ABBV) have been facing increasing completion from generic drugs following the expiration of patents on several blockbuster drugs. Drug companies are also evaluating the impact of President Obama's Affordable Care Act (ACA) on their bottom-line. StockCall free coverage on MRK, PFE, JNJ, and ABBV is available upon registration at http://www.stockcall.com/register Shares of Merck & Co. Inc. rose sharply in yesterday's trading session. The stock closed 1.61% higher at $43.66 after touching an intra-day high of $43.67. The drug maker's gains on Monday came on substantial volume, which suggests that market sentiment has turned bullish on the stock. This is confirmed by the stock's MACD chart. The MACD is currently trading above the signal line and the zero-line. Merck's shares are currently facing resistance at around $44. Year-to-date, its shares have gained more than 6.60%, underperforming the broad market. Download the free technical research on MRK by signing up at http://www.StockCall.com/MRK031213.pdf Shares of Pfizer Inc. posted modest gains in Monday's trading session. The stock closed 0.21% higher at $28.25. Pfizer's shares are currently trading close to their 52-week high of $28.38. The stock has had an excellent run this year, gaining more than 12%, compared to a gain of over 9% for the S&P 500. The stock recently broke through $27.50 resistance level, which is a bullish signal. The bullish trend is further confirmed by recent volume activity. The stock's MACD is also trading above the signal line. Register now and get access to the free analysis on PFE at http://www.StockCall.com/PFE031213.pdf Shares of Johnson & Johnson edged higher in its most recent trading session; however, the gains were limited. The stock closed 0.32% higher at $78.44 after touching a 52-week high of $78.52 on Monday. Johnson & Johnson's shares have gained more than 1% in the last three sessions. The drug maker's shares have seen a series of highs since the start of this year, which is a strong bullish signal. The upbeat trend is further confirmed by the stock's MACD chart. Sign up and read the complimentary report on JNJ at http://www.StockCall.com/JNJ031213.pdf Shares of AbbVie Inc. gained nearly 1% on Monday. The stock closed 0.88% higher at $37.67. AbbVie's shares have outperformed the broad market this year, gaining more than 10%. The stock is currently facing stiff resistance at $38.50. It has support at around $37. The company's shares are currently trading above their 50-day and 200-day moving averages. The free report on ABBV can be downloaded by signing up now at http://www.StockCall.com/ABBV031213.pdf About StockCall.com StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at http://www.stockcall.com SOURCE StockCall.com Contact: Contact Person:William T. Knight, Email: email@example.com, Contact Number: +1(646)396-9857 (9:00 am EST - 01:30 pm EST)
StockCall Study on Merck & Co., Pfizer, Johnson & Johnson, and AbbVie
Press spacebar to pause and continue. Press esc to stop.